Floatz logo

Imiquimod

Newly Diagnosed H3-mutated Glioma

German Cancer Research CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Newly Diagnosed H3-mutated Glioma cohort.

Asset / SponsorPhaseRating
Valproic Acid
University of Göttingen
Phase 3B
Cetuximab
University of Miami
Phase 1/2CCC
CBL-0137 FREE BASE
Children's Oncology Group
Phase 1/2CC
h3k27m peptide vaccine
German Cancer Research Center
Phase 1CC
Atezolizumab
German Cancer Research Center
Phase 1CC
VIPIVOTIDE TETRAXETAN
Memorial Sloan Kettering Cancer Center
Phase 1CC
Lorlatinib
Nationwide Children's Hospital
Early Phase 1C
azd1390
Children's Oncology Group
Phase 1NR

Same molecule, other indications

Imiquimod is also rated in:

lentigo maligna melanomaDormant
BBB
Indicative ·
77 / 100
View asset →
squamous cell intraepithelial neoplasiaDormant
B
Indicative ·
63 / 100
View asset →
human papilloma virus infectionDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →